Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methoxyflurane Combination vs Deep IV Sedation for Rezum in BPH
NCT07017452Phase 3Not yet recruiting
- Sponsor
- University of Manitoba
- Start
- Aug 2025
- Primary completion
- Dec 2025
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 3 trial of methoxyflurane in benign prostatic hyperplasia (BPH), sponsored by University of Manitoba. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
methoxyflurane
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT07017452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07017452.